Current trends of antibiotic resistance in clinical isolates of Staphylococcus aureus

Abstract

Staphyloccus aureus (S. aureus) is a well known human pathogen known to causes a verity of infections in humans. In recent years S. aureus is reported to show drug resistant toward commonly known drugs. Therefore, this study was designed to study the pattern of antibiotic resistance in 50 clinical isolates of S. aureus isolated at Dhanwantri Hospital and Research Centre, Jaipur, Rajasthan, India. S. aureus cultures were isolated from different clinical samples, pus, throat swabs and urine on Blood agar and MacConkey agar and Chrom agar plats and characterized by an array of microscopic and biochemical tests. Antibiotic sensitivity test was performed by standard disc diffusion method (Kirby bayer's method) on Muller Hinton agar plates. During this study, among 50  S. aureus isolates 48 (96%) were found to be resistance toward Aztreonam and Doxicycline followed by Ciprofloxacin (n = 45, 90%), Cefpodoxime and Ceftazidime (n = 44, 88%), Cefuroxime (n = 40, 80%), Pipracillin+ Tazobactum (n = 38, 76%), Cefoparazone (n = 36, 72%), Amoxicillin+ Clavulanic acid and Ceftriaxone (n = 33, 66%), Levofloxacin (n = 32, 64%), Moxifloxacin (n = 31, 62%), Ofloaxacin (n = 25, 50%), Cloxacillin (n = 22, 44%), Azithromycin (n = 21, 42%), Clindamycin (n = 19, 38%), Meropenem (n = 18, 36%), Clarithromycin (n = 16, 32%), Ampicillin+ sulbactam (n = 13, 26%), Amikacin (n = 12, 24%), Impipenem (n = 8, 16%), Linezolid and Methicillin (n = 7, 14%) and Teicoplanin (n = 3, 6%). In conclusion, the isolated S. aureus found to be resistant toward common antibiotics, however all isolates were found to be susceptible to Vancomycin.

Key words： Staphyloccus aureus; infections; antibiotic resistance

Acknowledgments

The authors wish to thank management of Dhanwantri Hospital and Research Centre, Jaipur, Rajasthan, India and Shri JJT University, Jhunjhunu, Rajasthan, India for providing necessary facilities and support for the completion of this work.

Compliance with ethics guidelines

Kapil Dev Sharma, Rajendra Prasad Saini, Loganathan Karthik declare that they have no conflict of interest. This article does not contain any studies with human or animal subjects performed by any of the authors.

References

1 Appelbaum P C (2006). MRSA—the tip of the iceberg. Clin Microbiol Infect, 12(s2 Suppl 2): 3−10

PMID

2 Bal A M, Gould I M (2005). Antibiotic resistance in Staphylococcus aureus and its relevance in therapy. Expert Opin Pharmacother, 6(13): 2257−2269

PMID

3 Bamberger D M, Boyd S E (2005). Management of Staphylococcus aureus infections. Am Fam Physician, 72(12): 2474−2481

PMID

4 Chambers H F (2001). The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis, 7(2): 178−182

PMID

5 Iqbal M, Ali K M, Daraz B, Siddique U (2004). Bacteriology of mastitic milk and in vitro antibiogram of the isolates. Pakistan Vet. J, 24: 161−164

6 Livermore D M (2000). Antibiotic resistance in staphylococci. Int J Antimicrob Agents, 16(Suppl 1): S3−S10

PMID

7 Lowy F D (2003). Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest, 111(9): 1265−1273

PMID

8 Pantosti A, Sanchini A, Monaco M (2007). Mechanisms of antibiotic resistance in Staphylococcus aureus. Future Microbiol, 2(3): 323−334

PMID

9 Rayner C, Munckhof W J (2005). Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus. Intern Med J, 35(s2 Suppl 2): S3−S16

PMID

10 WHO (1999). Leading cause of death.